PTC Therapeutics, Inc. was granted marketing authorization by the Eopean Commission for the gene therapy Upstaza a for the treatment of a rare genetic disease. This is good news for Swedish CombiGene, whose gene therapy CG01 for the treatment of epilepsy, which was out licensed to Spark Therapeutics in the autumn of 2021, like Upstaza, is intended to be administered directly into the brain of patients.